Advertisement
Advertisement
U.S. markets close in 1 hour 44 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Genscript Biotech Corporation (G51.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
3.2790-0.0970 (-2.87%)
As of 08:17AM CET. Market open.
Advertisement

Genscript Biotech Corporation

Jiangning Science Park
No. 28, Yongxi Road Jiangning District
Nanjing 211100
China
86 25 5889 7288
https://www.genscript.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees5,573

Key Executives

NameTitlePayExercisedYear Born
Mr. Jiange MengChairman442kN/A1968
Ms. Weihui ShaoCEO & COON/AN/A1981
Ms. Ye Wang M.S.Co-Founder, Pres & Exec. Director684kN/A1968
Mr. Shiniu WeiChief Financial OfficerN/AN/A1979
Dr. Li Zhu Ph.D.Chief Strategy Officer & Exec. Director265kN/A1950
Dr. Fangliang Zhang EMBA, Ph.D.Exec. DirectorN/AN/A1965
Dr. Chuan-Chu ChouHead of Discovery and Preclinical ServicesN/AN/A1954
Mr. Chifa ZhangDepartment Head of Industry Synthetic Biology Product SegmentN/AN/A1975
Dr. Brian Hosung MinCEO of Biologics Bus.N/AN/AN/A
Ms. Wai Ling Wong A.C.I.S., A.C.S., ACIS, ACSCompany Sec.N/AN/A1980
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.

Corporate Governance

Genscript Biotech Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement